Addressing advanced HIV disease and mortality in global HIV programming

Andrew T. Boyd, Ikwo Oboho, Heather Paulin, Hammad Ali, Catherine Godfrey, Anand Date, J. Sean Cavanaugh

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Introduction: The US President's Emergency Plan for AIDS Relief (PEPFAR) was launched to increase access to antiretroviral treatment (ART) among people living with HIV (PLHIV) and to prevent new HIV infections globally. As new infections have decreased in many PEPFAR-supported countries, PEPFAR is increasingly focusing on understanding and decreasing mortality among PLHIV, specifically by addressing advanced HIV disease (AHD) and its attendant opportunistic infections (OIs). Several developments in identifying AHD, in preventing, diagnosing, and treating selected OIs, and in PEPFAR's support for mortality surveillance make this an opportune moment for PEPFAR to address HIV-related mortality. Discussion: AHD upon diagnosis or re-engagement in HIV care is not uncommon, and it substantially increases risk of death from OIs. The World Health Organization provides evidence-based guidelines for a package of interventions for preventing, diagnosing, and treating common OIs, including tuberculosis (TB), cryptococcal meningitis, and severe bacterial infections. PEPFAR facilitates implementation of these guidelines. To identify PLHIV with low CD4, PEPFAR plans to support expanded access to CD4 testing, including a point-of-care assay that differentiates CD4 cell count as a binary of greater than or less than 200 cells/μL. To prevent AHD-related mortality, PEPFAR supports rapid ART initiation with integrase inhibitor-based regimens and implementation and documentation of TB preventive treatment. To diagnose selected OIs, PEPFAR is implementing urine lateral flow lipoarabinomannan use to identify TB among PLHIV who have a CD4 cell count < 200 cells/μL. To treat selected OIs, PEPFAR has focused on improving patient-centered care in TB/HIV co-infection services and scaling up implementation of new drug regimens for cryptococcal meningitis. To better understand mortality, PEPFAR has introduced an indicator, TX-ML, to routinely and systematically categorize outcomes, including deaths, among PLHIV on ART. Conclusions: PEPFAR is increasing its efforts to identify AHD; to prevent, diagnose, and treat OIs; and to track mortality in its programs. These ongoing efforts, done in collaboration with other stakeholders, seek to decrease mortality among PLHIV.

Original languageEnglish (US)
Article number40
JournalAIDS Research and Therapy
Volume17
Issue number1
DOIs
StatePublished - Jul 10 2020
Externally publishedYes

Keywords

  • Advanced HIV disease
  • HIV
  • Mortality
  • Opportunistic infections
  • PEPFAR
  • Tuberculosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Virology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Addressing advanced HIV disease and mortality in global HIV programming'. Together they form a unique fingerprint.

Cite this